Should I buy or sell Teva Pharmaceutical Industries stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TEVA shares. View TEVA analyst ratings or view top-rated stocks .

What is Teva Pharmaceutical Industries' stock price target for 2024?

10 Wall Street analysts have issued 12-month price targets for Teva Pharmaceutical Industries' stock. Their TEVA share price targets range from $10.00 to $19.00. On average, they expect the company's share price to reach $13.78 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price. View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts .

How have TEVA shares performed in 2024?

Teva Pharmaceutical Industries' stock was trading at $10.44 on January 1st, 2024. Since then, TEVA stock has increased by 22.4% and is now trading at $12.78. View the best growth stocks for 2024 here .

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 10,460,000 shares, a decline of 28.9% from the February 29th total of 14,720,000 shares. Based on an average daily trading volume, of 10,530,000 shares, the short-interest ratio is currently 1.0 days. View Teva Pharmaceutical Industries' Short Interest .

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TEVA earnings forecast .

How can I listen to Teva Pharmaceutical Industries' earnings call?

Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, May 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) released its earnings results on Wednesday, January, 31st. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.25. The company earned $4.46 billion during the quarter, compared to analysts' expectations of $3.97 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 34.90% and a negative net margin of 3.33%.

What ETFs hold Teva Pharmaceutical Industries' stock?

ETFs with the largest weight of Teva Pharmaceutical Industries (NYSE:TEVA) stock in their portfolio include VanEck Israel ETF (ISRA) , iShares MSCI Israel ETF (EIS) , VanEck Pharmaceutical ETF (PPH) and ARK Israel Innovative Technology ETF (IZRL) . iShares MSCI Intl Size Factor ETF (ISZE) .

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY24 earnings guidance on Wednesday, January, 31st. The company provided earnings per share (EPS) guidance of $2.20-$2.50 for the period, compared to the consensus EPS estimate of $2.41. The company issued revenue guidance of $15.7-$16.3 billion, compared to the consensus revenue estimate of $15.57 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com . Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE) , AT&T (T) , NVIDIA (NVDA) , Alibaba Group (BABA) , Intel (INTC) , Bank of America (BAC) , Micron Technology (MU) , Gilead Sciences (GILD) , Johnson & Johnson (JNJ) and Cisco Systems (CSCO) .

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.19%), IMC Chicago LLC (0.00%), Hennion & Walsh Asset Management Inc. (0.02%), Range Financial Group LLC (0.01%), Atlas Capital Advisors LLC (0.00%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Amir Weiss , David Matthew Stark , Eli Shani , Eliyahu Sharon Kalif , Eric A Hughes , Eric Drape , Hafrun Fridriksdottir , Mark Sabag , Pharmaceutical Co Ltd Takeda, Richard D Francis, Sven Dethlefs and Vikki L Conway. View institutional ownership trends .

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:TEVA

Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free TEVA Stock Alerts

$12.98

+0.20 (+1.56%)

(As of 11:22 AM ET)

Compare

Today's Range: $12.51
▼
$13.00
50-Day Range: $12.01
▼
$14.44
52-Week Range: $7.09
▼
$14.47

Volume: 3.45 million shs
Average Volume: 10.58 million shs
Market Capitalization: $14.55 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.78

Get Teva Pharmaceutical Industries alerts:

Teva Pharmaceutical Industries MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.70 Rating Score
Upside/Downside: 7.8% Upside
$13.78 Price Target
Short Interest: Healthy
1.03% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.87
Based on 12 Articles This Week
Insider Trading: Selling Shares
$5.13 M Sold Last Quarter
Proj. Earnings Growth: 10.09%
From $2.28 to $2.51 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.57 out of 5 stars

Medical Sector

668th out of 918 stocks

Pharmaceutical Preparations Industry

308th out of 430 stocks

2.4

Analyst's Opinion

Consensus Rating
Teva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Teva Pharmaceutical Industries has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.03% of the outstanding shares of Teva Pharmaceutical Industries have been sold short.
Short Interest Ratio / Days to Cover
Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Teva Pharmaceutical Industries has recently increased by 10.52%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Teva Pharmaceutical Industries does not currently pay a dividend.
Dividend Growth
Teva Pharmaceutical Industries does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TEVA.

2.7

News and Social Media Coverage

News Sentiment
Teva Pharmaceutical Industries has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Teva Pharmaceutical Industries this week, compared to 6 articles on an average week.
Search Interest
Only 22 people have searched for TEVA on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
MarketBeat Follows
Only 13 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is a decrease of -35% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,132,766.00 in company stock.
Percentage Held by Insiders
Only 0.62% of the stock of Teva Pharmaceutical Industries is held by insiders.
Percentage Held by Institutions
54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Teva Pharmaceutical Industries are expected to grow by 10.09% in the coming year, from $2.28 to $2.51 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Teva Pharmaceutical Industries is -27.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Teva Pharmaceutical Industries is -27.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Teva Pharmaceutical Industries has a PEG Ratio of 1.58. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Teva Pharmaceutical Industries has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Teva Pharmaceutical Industries Stock (NYSE:TEVA)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

TEVA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TEVA Stock News Headlines

April 19, 2024 | msn.com

Number of Cape pharmacies ditch Israeli medicines to become ‘Apartheid Free Zone’

April 19, 2024 | msn.com

Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S.

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 19, 2024 | americanbankingnews.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) to Post Q2 2025 Earnings of $0.57 Per Share, Zacks Research Forecasts

April 16, 2024 | finance.yahoo.com

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets

April 14, 2024 | americanbankingnews.com

Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 5.3%

April 13, 2024 | americanbankingnews.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Average Recommendation of "Moderate Buy" from Analysts

April 11, 2024 | msn.com

Pfizer unit to settle Effexor XR antitrust claims in $39M deal

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 11, 2024 | markets.businessinsider.com

Teva Confirms Efficacy, Safety Of AJOVY In Prevention Of Migraine - Quick Facts

April 11, 2024 | businesswire.com

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

April 10, 2024 | americanbankingnews.com

Stock Traders Buy High Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)

April 9, 2024 | businesswire.com

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

April 6, 2024 | finance.yahoo.com

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

April 6, 2024 | businesswire.com

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

April 4, 2024 | finance.yahoo.com

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

April 3, 2024 | msn.com

Biden touts inhaler price drops with Bernie Sanders: "Finally, finally we beat big Pharma"

April 1, 2024 | reuters.com

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

April 1, 2024 | finance.yahoo.com

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement

March 28, 2024 | msn.com

Experts say Medicaid rebate change is behind inhaler price cuts

March 28, 2024 | seekingalpha.com

Teva stock trades in the green for seventh straight session

March 27, 2024 | benzinga.com

Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity

March 27, 2024 | finance.yahoo.com

Teva Pharmaceutical Industries Limited: HOLD on weak near-term earnings outlook

March 26, 2024 | finance.yahoo.com

Institutional investors have a lot riding on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 67% ownership

March 25, 2024 | seekingalpha.com

Teva Pharmaceutical Industries: Potential Outweighs Concerns

March 24, 2024 | finance.yahoo.com

25 Countries with the Lowest Fertility Rates

March 14, 2024 | finance.yahoo.com

TEVA Mar 2024 20.000 call

See More Headlines

Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 1/31/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:TEVA
CUSIP: N/A
CIK: 818686
Web: www.tevapharm.com
Phone: (723) 914-8213
Fax: 972-3923-4050
Employees: 37,851
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.78
High Stock Price Target: $19.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +7.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.70
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 5.61
P/E Growth: 1.58
Net Income: $-559,000,000.00
Net Margins: -3.33%
Pretax Margin: -3.94%
Return on Equity: 34.90%
Return on Assets: 6.48%

Debt

Debt-to-Equity Ratio: 2.23
Current Ratio: 1.02
Quick Ratio: 0.69

Sales & Book Value

Annual Sales: $15.85 billion
Price / Sales: 0.90
Cash Flow: $3.41 per share
Price / Cash Flow: 3.75
Book Value: $7.25 per share
Price / Book: 1.76

Miscellaneous

Outstanding Shares: 1,121,090,000
Free Float: 1,114,143,000
Market Cap: $14.33 billion
Optionable: Optionable
Beta: 1.05

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Eliyahu Sharon Kalif (Age 51)
Executive VP & CFO
Comp: $2.01M
Mr. Eric Drape (Age 62)
Executive Vice President of Global Operations
Comp: $1.91M
Mr. Mark Sabag (Age 53)
Executive Vice President of International Markets Commercial
Comp: $1.92M
Mr. Richard D. Francis (Age 56)
President, CEO & Director
Mr. Amir Weiss (Age 47)
Senior VP & Chief Accounting Officer
Ran Meir
Head of Investor Relations
Dov Bergwerk
Acting Chief Legal Officer & Corporate Secretary
Kathleen Veit
Senior Vice President, Global Compliance & Ethics Officer
Ms. Vikki Conway
Acting Head of Global Human Resources
Mr. Kevin C. Mannix
Senior Vice President of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TEVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TEVA shares.
View TEVA analyst ratings or view top-rated stocks.
What is Teva Pharmaceutical Industries' stock price target for 2024?: 10 Wall Street analysts have issued 12-month price targets for Teva Pharmaceutical Industries' stock. Their TEVA share price targets range from $10.00 to $19.00. On average, they expect the company's share price to reach $13.78 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price.
View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts.
How have TEVA shares performed in 2024?: Teva Pharmaceutical Industries' stock was trading at $10.44 on January 1st, 2024. Since then, TEVA stock has increased by 22.4% and is now trading at $12.78.
View the best growth stocks for 2024 here.
Are investors shorting Teva Pharmaceutical Industries?: Teva Pharmaceutical Industries saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 10,460,000 shares, a decline of 28.9% from the February 29th total of 14,720,000 shares. Based on an average daily trading volume, of 10,530,000 shares, the short-interest ratio is currently 1.0 days.
View Teva Pharmaceutical Industries' Short Interest.
When is Teva Pharmaceutical Industries' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TEVA earnings forecast.
How can I listen to Teva Pharmaceutical Industries' earnings call?: Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, May 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Teva Pharmaceutical Industries' earnings last quarter?: Teva Pharmaceutical Industries Limited (NYSE:TEVA) released its earnings results on Wednesday, January, 31st. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.25. The company earned $4.46 billion during the quarter, compared to analysts' expectations of $3.97 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 34.90% and a negative net margin of 3.33%.

What ETFs hold Teva Pharmaceutical Industries' stock?: ETFs with the largest weight of Teva Pharmaceutical Industries (NYSE:TEVA) stock in their portfolio include VanEck Israel ETF (ISRA), iShares MSCI Israel ETF (EIS), VanEck Pharmaceutical ETF (PPH) and ARK Israel Innovative Technology ETF (IZRL).iShares MSCI Intl Size Factor ETF (ISZE).
What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?: Teva Pharmaceutical Industries issued an update on its FY24 earnings guidance on Wednesday, January, 31st. The company provided earnings per share (EPS) guidance of $2.20-$2.50 for the period, compared to the consensus EPS estimate of $2.41. The company issued revenue guidance of $15.7-$16.3 billion, compared to the consensus revenue estimate of $15.57 billion.
What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?: 158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.
What other stocks do shareholders of Teva Pharmaceutical Industries own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).
Who are Teva Pharmaceutical Industries' major shareholders?: Teva Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.19%), IMC Chicago LLC (0.00%), Hennion & Walsh Asset Management Inc. (0.02%), Range Financial Group LLC (0.01%), Atlas Capital Advisors LLC (0.00%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Amir Weiss, David Matthew Stark, Eli Shani, Eliyahu Sharon Kalif, Eric A Hughes, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard D Francis, Sven Dethlefs and Vikki L Conway.
View institutional ownership trends.
How do I buy shares of Teva Pharmaceutical Industries?: Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:TEVA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial